Start
Entdecken
nav.journalClub
Trends
Mehr
synapse
⌘+K
Sprache
Deutsch
Deutsch
March 3, 2026
Once-Daily Foscarnet As a Treatment Strategy for HHV-6 Reactivation after Allogeneic Stem Cell Transplantation
PC
Piyatida Chumnumsiriwath
University of California, Irvine
PV
Pongthep Vittayawacharin
Siriraj Hospital
BL
Benjamin Lee
See all
Key Points
Foscarnet effectively reduces HHV-6 reactivation following allogeneic stem cell transplantation, improving patient outcomes.
A significant metric is the observed decrease in reactivation rates among treated patients over time.
The trial utilized an observational analysis across several centers focusing on treatment response rates.
This new approach highlights the potential benefits of antiviral strategies following stem cell transplants, warranting further exploration.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Chumnumsiriwath et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7609bc6e9836116a2d87f
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.820
Once-Daily Foscarnet As a Treatment Strategy for HHV-6 Reactivation after Allogeneic Stem Cell Transplantation | Synapse